Hutchmed China Limited Adr (HCM)

Wall Street Analysts Think HUTCHMED (HCM) Could Surge 102.73%: Read This Before Placing a Bet - Yahoo New Zealand News

Yahoo New Zealand News

HUTCHMED to Announce 2024 Half-Year Financial Results

GlobeNewswire Inc.

HUTCHMED: Data at EHA 2024 heighten focus on sovleplenib - Research Tree

Research Tree

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

GlobeNewswire Inc.

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

GlobeNewswire Inc.

Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

HUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Update - MarketBeat

MarketBeat

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

GlobeNewswire Inc.

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China - Yahoo Finance UK

Yahoo Finance UK

Hsbc Holdings PLC Buys 184123 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Defense World

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Trexquant Investment LP - Defense World

Defense World

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Trexquant Investment LP - Defense World

Defense World

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by BNP Paribas Financial Markets - Defense World

Defense World

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

GlobeNewswire Inc.

《AI》HUTCHMED(00013.HK) Displays Technical Pattern of Death Cross - AASTOCKS.com

AASTOCKS.com

International companies to host live webcasts at Deutsche Bank's Depositary Receipts - Quantisnow

Quantisnow

HUTCHMED (LON:HCM) Stock Crosses Above Two Hundred Day Moving Average of $271.48 - Defense World

Defense World

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire Inc.

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board ... - GlobeNewswire

GlobeNewswire

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board ... - Yahoo Finance UK

Yahoo Finance UK

HUTCHMED (LON:HCM) Stock Crosses Above 200-Day Moving Average of $271.21 - Defense World

Defense World

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board ... - GlobeNewswire

GlobeNewswire

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

GlobeNewswire Inc.

TCOM: 3 China Stocks to Watch in May - StockNews.com

StockNews.com

TCOM: 3 China Stocks to Watch in May - StockNews.com

StockNews.com

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

GlobeNewswire Inc.

ACHV: First Quarter Results - Research Tree

Research Tree

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire Inc.

M Stanley Lowers INNOVENT BIO (01801.HK) TP to $66.5, Cuts KEYMED BIO-B (02162.HK) TP to $50 - AASTOCKS.com

AASTOCKS.com

HUTCHMED (LON:HCM) Shares Pass Above 200-Day Moving Average of $268.65 - Defense World

Defense World

HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? - Zacks Investment Research

Zacks Investment Research

Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect? - Zacks Investment Research

Zacks Investment Research

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

GlobeNewswire Inc.

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer ... - GlobeNewswire

GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

GlobeNewswire Inc.

HUTCHMED to Disclose Several Research Data at AACR Annual Meeting - AASTOCKS.com

AASTOCKS.com

Hutchmed endometrial cancer treatment gets priority review in China - ShareCast

ShareCast

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

GlobeNewswire Inc.

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

GlobeNewswire Inc.

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

GlobeNewswire Inc.

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

Benzinga

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

GlobeNewswire Inc.

Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

Zacks Investment Research

Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga